Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Strabismus, Dystonia, Cardiac arrest, and Flexion contracture and others; and common findings: Kyphoscoliosis, Absent speech, Umbilical hernia, and Severe intellectual disability and others. 55 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 7 | Moderate intellectual disability, Dystonia, Absent speech |
TOR1A function has not been fully characterized.
Arthrogryposis multiplex congenita 5 is associated with mutations in the TOR1A gene on chromosome 9.
No clinically relevant genotype-phenotype correlations have been identified.
No consensus clinical diagnostic criteria for DYT-TOR1A have been published.
DYT-TOR1A should be suspected in probands with the following clinical and supportive imaging findings and family history. Clinical findings
Onset is in childhood or adolescence (median age: 9 years; interquartile range: 7-12 years).
Dystonia usually begins in a leg (average age: 9 years) or an arm (average age: 15 years).
No approved treatments are currently available for arthrogryposis multiplex congenita 5. The disease remains an area of unmet medical need.
No clinical practice guidelines for DYT-TOR1A have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with DYT-TOR1A, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. DYT-TOR1A: Recommended Evaluations Following Initial Diagnosis
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 5. DYT-TOR1A: Recommended Surveillance
No clinical trials have been registered for arthrogryposis multiplex congenita 5.
2 publications have been identified in PubMed for arthrogryposis multiplex congenita 5. Research spans Review / Meta-Analysis (50%) and Case Report / Case Series (50%).
He C (2025). [PMID: 39593234](https://pubmed.ncbi.nlm.nih.gov/39593234/). *Anim Genet*. [Case Report / Case Series]
Pérez-Vidarte F (2025). [PMID: 40443119](https://pubmed.ncbi.nlm.nih.gov/40443119/). *Ann Clin Transl Neurol*. [Review / Meta-Analysis]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 3:32 AM UTC
Online Mendelian Inheritance in Man
Common questions about arthrogryposis multiplex congenita 5
Muscles |
5 |
Flexion contracture, Generalized hypotonia, Elbow flexion contracture |
Eyes | 3 | Strabismus, Ptosis, Optic disc pallor |
Arms and legs | 3 | Hand clenching, Hand tremor, Rocker bottom foot |
Head and neck | 2 | Round face, Microcephaly |
Bones and joints | 2 | Kyphoscoliosis, Sideways curvature of the spine (scoliosis) |
Lungs and breathing | 2 | Restrictive ventilatory defect, Neonatal respiratory distress |
Pregnancy and birth | 2 | Decreased fetal movement, Neonatal respiratory distress |
Growth and development | 2 | Intrauterine growth retardation, Growth delay |
Heart and blood vessels | 1 | Cardiac arrest |
Blood and immune system | 1 | Normocytic anemia |
Kidneys and urinary system | 1 | Medullary nephrocalcinosis |
Digestive system | 1 | Gastrostomy tube feeding in infancy |
Skin | 1 | Premature skin wrinkling |
Age of onset: infancy.
DYT1-TOR1A is an early-onset isolated dystonia with a median age of onset of nine years (interquartile range: 7-12 years); approximately 5% of individuals have onset after age 30 years . Onset is typically in an arm or a leg; however, when dystonia becomes generalized, axial and cervical involvement are common. Craniofacial or laryngeal involvement is uncommon. Presentation. Onset is usually in a leg (average age: 9 years) or an arm (average age: 15 years). Initially, dystonia is apparent with specific actions such as a change in gait (foot inversion or eversion, abnormal flexion of the knee or hip) or writer's cramp (dystonia of the upper extremity that is task specific to writing caused by tightening and/or posturing of the upper extremity).
Source: GeneReviews — "DYT-TOR1A"
Source: GeneReviews — "DYT-TOR1A"
TOR1A deletion is approximately 30% . Thus, on average, 30% of individuals who inherit this variant will develop DYT-TOR1A and 70% will not.
Source: GeneReviews — "DYT-TOR1A"
Initiation or worsening of dystonic movements and postures often follows voluntary movements.
Absence of:
Other neurologic or systemic manifestations
A history of a known cause of acquired dystonia (See .)
Imaging findings. Brain CT and routine MRI are normal.
Family history
Source: GeneReviews — "DYT-TOR1A"
DYT-TOR1A is estimated to account for approximately 16%-53% of early-onset dystonia in individuals who are not of Jewish ancestry and approximately 80%-90% of early-onset dystonia in the Ashkenazi Jewish population . In broader cohort studies involving individuals with various subtypes of isolated dystonia, DYT-TOR1A accounts for a low percentage of dystonia because isolated adult-onset focal dystonia (e.g., cervical dystonia) is far more common than early-onset isolated dystonia [, , , , , ]. Genetic disorders that may present with early-onset isolated dystonia in a limb and are in the differential diagnosis of DYT-TOR1A are listed in . Table 2. DYT-TOR1A: Differential Diagnosis
Gene | Disorder | MOI | Features of Disorder Overlapping w/DYT-TOR1A | Features of Disorder Distinguishing from DYT-TOR1A/ Comment |
|---|---|---|---|---|
ANO3 | DYT-ANO31 | AD | May present as isolated limb dystonia or generalized dystonia | ANO3 pathogenic variants are assoc w/broad phenotypic spectrum ranging from focal craniocervical to generalized dystonia to combined dystonia involving myoclonus parkinsonism.2 |
AOPEP | DYT-AOPEP1 | AR | Progressive dystonia affecting extremities; Variable craniocervical involvement | Recently described; data are limited. |
EIF2AK | DYT-EIF2AK1 | ADAR | May rarely be assoc w/isolated limb dystonia | EIF2AK pathogenic variants are more commonly assoc w/complex neurologic syndromes that do not involve dystonia. |
EIF4A2 | EIF4A2-related dystonia1 | AD | Adolescent- to adult-onset dystonia w/tremor | EIF4A2 pathogenic variants are more commonly assoc w/neurodevelopmental delay.; EIF4A2-related dystonia is recently described; limited data are available. |
GCH1 | GTP cyclohydrolase 1-deficient dopa-responsive dystonia (DYT/PARK-GCH13) | AD | Childhood-onset limb dystonia | Marked sustained response to low-dose levodopa; Diurnal fluctuation is seen in many affected persons. GNAL |
DYT-GNAL | AD(typically)4 | Isolated dystonia (onset in childhood is rare) | Typically adult-onset focal/segmental dystonia; rarely generalizes | — |
HPCA | DYT-HPCA1 | AR | May present as isolated dystonia | Infancy to early adult onset; Phenotype ranges from isolated dystonia to complex syndrome w/neurodevelopmental delay, infantile seizures, dystonia.; Small number of reported persons |
KMT2B | KMT2B-related dystonia (DYT-KMT2B) | AD | May present as isolated childhood-onset limb/truncal dystonia; DBS has resulted in substantial clinical functional improvement. | Cranial/pharyngeal involvement is common.; In most persons, dystonia is accompanied by additional neurologic or systemic manifestations, as in complex dystonia.; Intellectual disability/ developmental delay are common. |
PRKRA | DYT-PRKRA1 | AR | Early-onset focal dystonia followed by generalization | Not responsive to anticholinergic drugs; PRKRA pathogenic variants are also assoc w/familial ... |
Source: GeneReviews — "DYT-TOR1A"
Genetic testing for TOR1A is available. Testing is considered confirmatory for diagnosis.
System/Concern | Evaluation | Comment |
|---|---|---|
Movement disorders | Complete neurologic exam by movement disorders specialist | Assess dystonia make treatment recommendations.; May use Burke-Fahn-Marsden Dystonia Rating Scale1 |
Activities of daily living | Physiatry (physical medicine rehab), physical therapy, occupational therapy | Consider need for durable medical equipment (e.g., adaptive strollers, wheelchairs, walkers, bath chairs, orthotics). |
Musculoskeletal | Eval by orthopedist | If appropriate, assess for secondary complications incl fixed contractures, joint dislocation, /or kyphoscoliosis. |
Educational needs | Young children: eval by developmental pediatrician | Assess need for early intervention program. School-age children: educational assessment |
Psychiatric manifestations | Psychiatric eval | To assess for depression /or anxiety related to their illness/disability |
Genetic counseling | By genetics professionals2 | To obtain a pedigree inform affected persons their families re nature, MOI, implications of DYT-TOR1A to facilitate medical personal decision making Family support |
resources | By clinicians, wider care team, family support organizations | Assessment of family social structure to determine need for:; Community or such as Parent to Parent; Social work involvement for parental support IEP = individualized education plan; MOI = mode of inheritance 1. |
Source: GeneReviews — "DYT-TOR1A"
Unless medically necessary, avoid immobilization with bracing or casting of the parts of the body affected by dystonia, which can worsen the dystonia.
Source: GeneReviews — "DYT-TOR1A"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "DYT-TOR1A"
View trials for arthrogryposis multiplex congenita 5
Evaluation |
|---|
Frequency |
|---|
Neurologic | Assessment of progression of known features, emergence of new manifestations, response to treatment by neurologist specializing in movement disorders | Every 3-6 mons; Possibly more frequently in period following DBS to optimize effectiveness |
Development | Monitor developmental progress educational needs. | At each visit Growth, weight, nutrition |
Psychiatric manifestations | For those known to have mental health issues: monitor response to interventions emergence of new issues. | Per treating clinician For those not known to have mental health issues: assess for depression anxiety. |
Family/Community | Assess family need for social work support, care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning). | At each visit DBS= deep brain stimulation; OT = occupational therapy; PT = physical therapy |
Source: GeneReviews — "DYT-TOR1A"
Phenotype severity distribution: 45 always present features, 6 common features.